Treatment Effectiveness of Shifting from Risperidone Long-acting Injectable to First-generation Long-acting Injectable Antipsychotics in Patients with Schizophrenia

10.4103/TPSY.TPSY_27_19

Ching-Yin Chang；Hung-Yu Chan

extrapyramidal symptoms ； nonadherence ； side effects of antipsychotic drugs ； time to hospitalization

台灣精神醫學

33卷3期（2019 / 09 / 01）

135 - 141

英文

Objectives: Most studies of long-acting injectable antipsychotic (LAI) drugs have been focused on the efficacy of second-generation antipsychotic (SGA) LAIs through observation of the various outcomes of shifting from first-generation antipsychotic (FGA) LAIs to SGA LAIs. Rare studies have assessed the effectiveness of shifting from SGA LAIs to FGA LAIs. In this study, we intended to investigate the effectiveness of shifting from risperidone LAI to FGA LAIs in patients with schizophrenia. Methods: We included patients with schizophrenia and with the ownership of catastrophic illness card in the study. All the study patients had received risperidone LAI at least two months with a minimal dose of 50 mg per month. The case group included the patients who had been shifting from risperidone LAI to FGA LAIs (fluphenazine, haloperidol, or flupentixol). The control group included the patients who were continuously maintaining on risperidone LAI. The primary outcome was the time to hospitalization. The secondary outcomes were the side effects requiring to receive the use of concomitant anticholinergics, propranolol, and benzodiazepines. Results: We had 15 patients in the case group and 98 patients in the control group. The primary outcomes showed no significant between-group difference in the time to hospitalization (hazard ratio = 3.676, 95% confidence interval = 0.833 - 16.222). The secondary outcomes also showed no significant differences between the case and control groups. Conclusion: This study showed no significant differences in the treatment effectiveness and side effects between FGA LAIs and risperidone LAI. The results are compatible with those from a previous LAI study from the National Institute of Mental Health of the United States. But the relatively small effect with inadequate statistical power is the major study limitation, which may produce no significant differences in side effects. We suggest that further large-sample study is needed to confirm the results of this study.

1. Chan, HY,Pan, YJ,Chen, JJ(2017).Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic, comparative study.J Clin Psychopharmacol,37,13-20.
2. Charlson, ME(1993).Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: a response.J Clin Epidemiol,46,1083-1084.
3. Covell, NH,McEvoy, JP,Schooler, NR(2012).Effectiveness of switching from long‑acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.J Clin Psychiatry,73,669-675.
4. Hawley, C,Turner, M,Latif, MA(2010).Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.Hum Psychopharmacol,25,37-46.
5. Huang, SS,Lin, CH,Loh, el-W(2013).Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.Psychiatr Serv,64,1259-1262.
6. Keith, SJ,Kane, JM(2003).Partial compliance and patient consequences in schizophrenia: our patients can do better.J Clin Psychiatry,64,1308-1315.
7. Keith, SJ,Kane, JM,Turner, M(2004).Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.J Clin Psychiatry,65,120-131.
8. Kishimoto, T,Robenzadeh, A,Leucht, C(2014).Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Schizophr Bull,40,192-213.
9. Lammers, L,Zehm, B,Williams, R(2013).Risperidone long-acting injection in schizophrenia spectrum illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.BMC Psychiatry,13,155.
10. Law, MR,Soumerai, SB,Ross-Degnan, D(2008).A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.J Clin Psychiatry,69,47-53.
11. Leucht, C,Heres, S,Kane, JM(2011).Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials.Schizophr Res,127,83-92.
12. Leucht, S,Corves, C,Arbter, D(2009).Second-generation versus first‑generation antipsychotic drugs for schizophrenia: a meta‑analysis.Lancet,373,31-41.
13. Leucht, S,Samara, M,Heres, S(2016).Dose equivalents for antipsychotic drugs: the DDD method.Schizophr Bull,42(Suppl 1),S90-S94.
14. Lieberman, JA,Stroup, TS,McEvoy, JP(2005).Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med,353,1209-1223.
15. Lloyd, K,Latif, MA,Simpson, S(2010).Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.Hum Psychopharmacol,25,243-252.
16. McEvoy, JP,Byerly, M,Hamer, RM(2014).Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.JAMA,311,1978-1987.
17. Möller, HJ(2007).Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.Drugs,67,1541-1566.
18. Nielsen, J,Jensen, SO,Friis, RB(2015).Comparative effectiveness of risperidone long‑acting injectable vs. first‑generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.Schizophr Bull,41,627-636.
19. Porcelli, S,Bianchini, O,De Girolamo, G(2016).Clinical factors related to schizophrenia relapse.Int J Psychiatry Clin Pract,20,54-69.
20. Rosenheck, RA,Leslie, DL,Sint, KJ(2016).Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia.Psychiatr Serv,67,1124-1130.
21. Schooler, NR(2003).Relapse and rehospitalization: comparing oral and depot antipsychotics.J Clin Psychiatry,64(Suppl 16),14-17.
22. Schooler, NR,Keith, SJ,Severe, JB(1997).Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment.Arch Gen Psychiatry,54,453-463.
23. Taylor, D(2009).Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review.Br J Psychiatry Suppl,52,S13-S19.
24. Valenstein, M,Blow, FC,Copeland, LA(2004).Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.Schizophr Bull,30,255-264.
25. Wang, CY,Xiang, YT,Cai, ZJ(2010).Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.Am J Psychiatry,167,676-685.
26. Weiden, PJ,Kozma, C,Grogg, A(2004).Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia.Psychiatr Serv,55,886-891.
27. Wu, CS,Cheng, IC,Feng, J(2016).Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: a nationwide population-based cohort study.Schizophr Res,173,37-44.
28. Yu, HY,Hsiao, CY,Chen, KC(2015).a comparison of the effectiveness of risperidone, haloperidol and flupentixol long‑acting injections in patients with schizophrenia – a nationwide study.Schizophr Res,169,400-405.